Latest documents http://publikationen.ub.uni-frankfurt.de/index/index/ Tue, 22 May 2007 15:26:12 +0200 Tue, 22 May 2007 15:26:12 +0200 http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/1036 Following publication of the data presented by von Minckwitz and colleagues [1] it has been brought to our attention that some patients should be scored differently. Stable disease was seen in three of the eighteen patients instead of two of the eighteen patients: one patient with transitional cell carcinoma treated at 4 micro g/kg scFv(FRP5)-ETA per day, and two breast cancer patients treated at 4 and 12.5 micro g/kg scFv(FRP5)-ETA per day. Disease progression occured in 9 of the eighteen patients evaluated (see corrected Table 2 overleaf). This does not affect the conclusions of our study. In addition we would like to correct the following errors: patient IDs for patients U01 and U02 in the original Table 2 were interchanged. In addition, patient N03 had a grade 3 elevation of gamma-glutamyl transferase, and not grade 2 (see corrected Table 2 overleaf). http://publikationen.ub.uni-frankfurt.de/volltexte/2005/1156/ Gunter von Minckwitz; Sebastian Harder; Sascha Hövelmann; Elke Jäger; Salah-Eddin Al-Batran; Sibylle Loibl; Akin Atmaca; Christian Cimpoiasu; Antje Neumann; Aklil Abera; Alexander Knuth; Manfred Kaufmann; Dirk Jäger; Alexander B. Maurer; Winfried S. Wels article http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/1036 Tue, 22 May 2007 15:26:12 +0200